IP Library Granted Patent US 11,648,199
Granted Patent B2
US 11,648,199 · App. 17/301,316 · Granted May 16, 2023

Inhalable rapamycin formulation for treating age-related conditions

Inventors: Thomas Armer (Palo Alto, CA); Lawrence S. Melvin, Jr. (Niwot, CO); Jonathan M. Rothberg (Guilford, CT); Henri Lichenstein (Guilford, CT)
Assignee: Al Therapeutics, Inc.
A61K9/0075A61K9/145A61K31/436A61K45/06A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,648,199
App. No.
17/301,316
Granted
May 16, 2023
Kind
B2
Abstract

The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.

Claims (14)

1. A pharmaceutical composition in the form of an inhalable dry powder consisting essentially of microparticles of rapamycin and particles of a carrier, wherein the composition does not contain a surfactant or other additives.

2. The pharmaceutical composition of claim 1 , wherein the amount of rapamycin in the composition is from 0.1% to 20% (w/w) or from 0.25% to 2% (w/w), based upon the total weight of the composition.

3. The pharmaceutical composition of claim 1 , wherein the microparticles of rapamycin have an MMAD of from 2 to 3 microns.

4. The pharmaceutical composition of claim 1 , wherein the carrier is selected from the group consisting of arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran, and mannitol.

5. The pharmaceutical composition of claim 1 , wherein the particles of the carrier have diameters ranging from 1 to 200 microns, from 30 to 100 microns, or less than 10 microns.

6. The pharmaceutical composition of claim 1 , wherein the carrier is a blend of two different carriers, a first carrier and a second carrier.

7. The pharmaceutical composition of claim 6 , wherein the first carrier consists of particles having diameters ranging from 30-100 microns and the second carrier consists of particles having diameters of less than 10 microns.

8. The pharmaceutical composition of claim 6 , wherein the carrier consists of a blend of two different lactose carriers.

9. The pharmaceutical composition of claim 1 , wherein the rapamycin has an isomeric B:C ratio of greater than 30:1 or greater than 35:1.

10. The pharmaceutical composition of claim 1 , wherein the surfactant additive excluded from the composition includes polyethylene glycol (PEG)-fatty acids and PEG-fatty acid mono and diesters, PEG glycerol esters, alcohol-oil transesterification products, polyglyceryl fatty acids, propylene glycol fatty acid esters, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar and its derivatives, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene (POE-POP) block copolymers, sorbitan fatty acid esters, ionic surfactants, fat-soluble vitamins and their salts, water-soluble vitamins and their amphiphilic derivatives, amino acids and their salts, and organic acids and their esters and anhydrides.

11. A pharmaceutical composition in the form of an inhalable dry powder consisting essentially of microparticles of rapamycin and particles of a carrier, wherein the microparticles of rapamycin consist of particles having a Mass Median Aerodynamic Diameter (MMAD) of from 1 to 5 microns, and wherein the composition does not contain a surfactant or other additives.

12. The pharmaceutical composition of claim 11 , wherein the carrier is a lactose carrier or a blend of two different lactose carriers.

13. The pharmaceutical composition of claim 12 , wherein the microparticles of rapamycin have an MMAD of from 2 to 3 microns.

14. The pharmaceutical composition of claim 13 , wherein the surfactant additive excluded from the composition includes polyethylene glycol (PEG)-fatty acids and PEG-fatty acid mono and diesters, PEG glycerol esters, alcohol-oil transesterification products, polyglyceryl fatty acids, propylene glycol fatty acid esters, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar and its derivatives, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene (POE-POP) block copolymers, sorbitan fatty acid esters, ionic surfactants, fat-soluble vitamins and their salts, water-soluble vitamins and their amphiphilic derivatives, amino acids and their salts, and organic acids and their esters and anhydrides.

Assignments (5)
SECURITY INTEREST Recorded Feb 18, 2026
From: ORPHAI THERAPEUTICS INC.
To: ACADIA WOODS PARTNERS, LLC, AS AGENT
Reel/Frame 074910/0274 →
SECURITY INTEREST Recorded Jun 23, 2025
From: ORPHAI THERAPEUTICS INC.
To: ACADIA WOODS PARTNERS, LLC
Reel/Frame 071697/0788 →
CHANGE OF NAME Recorded Oct 4, 2023
From: AI THERAPEUTICS, INC.
To: ORPHAI THERAPEUTICS INC.
Reel/Frame 065120/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: ARMER, THOMAS; MELVIN, LAWRENCE S., JR.; ROTHBERG, JONATHAN M.; LICHENSTEIN, HENRI
To: LAM THERAPEUTICS, INC.
Reel/Frame 055785/0202 →
CHANGE OF NAME Recorded Mar 31, 2021
From: LAM THERAPEUTICS, INC.
To: AI THERAPEUTICS, INC.
Reel/Frame 055790/0984 →
Continuity (4)
Continuation 16042534 · Jul 23, 2018
Continuation 15301252
Provisional Application 61975127 · Apr 4, 2014
Related Publication 20210212942A1 · Jul 15, 2021